Hannah Rahim
Hannah Rahim has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Seth Kesselheim
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
1 shared publication - Amina Mohamud
Departments of Pediatrics and Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
1 shared publication - Ian A. Lewis
University of Calgary
1 shared publication Kyle L. Flannigan
Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
1 shared publication- Michael R. Taylor
Departments of Pediatrics and Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
1 shared publication - Simon Andrew Hirota
University of Calgary
1 shared publication
Latest Publications
- 30 May 2025
- Published by Wiley in The Milbank Quarterly
National Analysis of the Requirements and Implementation of State Prescription Drug Price Transparency Laws
Policy Points: A total of 21 states have passed drug price transparency laws with the goals of creating accountability around drug pricing and facilitating the development of policy solutions to address high prices. These laws vary in design but often require manufacturers to report the wholesale acquisition cost of drugs above a certain threshold for new drugs or of drugs that undergo a price increase above a certain margin, along with other data such as the manufacturer's costs. Initial findings suggest these laws may have contributed toward informing policymaking based on newly available public information but do not appear to have affected drug prices.
- 30 May 2025
- Published by Wiley in The Milbank Quarterly
National Analysis of the Requirements and Implementation of State Prescription Drug Price Transparency Laws
Policy Points: A total of 21 states have passed drug price transparency laws with the goals of creating accountability around drug pricing and facilitating the development of policy solutions to address high prices. These laws vary in design but often require manufacturers to report the wholesale acquisition cost of drugs above a certain threshold for new drugs or of drugs that undergo a price increase above a certain margin, along with other data such as the manufacturer's costs. Initial findings suggest these laws may have contributed toward informing policymaking based on newly available public information but do not appear to have affected drug prices.
- Open Access
- 2 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (8) , eaax2358
Vancomycin relieves mycophenolate mofetil–induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity
Toxicity from the immunosuppressant mycophenolate mofetil is prevented by eliminating gut bacteria expressing β-glucuronidase.
- 2 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (8) , eaax2358
Open AccessVancomycin relieves mycophenolate mofetil–induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity
Toxicity from the immunosuppressant mycophenolate mofetil is prevented by eliminating gut bacteria expressing β-glucuronidase.